Helle Pappot

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

J. Alfred Witjes, Marek Babjuk, Joaquim Bellmunt et al. · European Urology · 2019 · 192 citations · Full text

Medicine, Oncology, Urology +16

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Alan Horwich, Marek Babjuk, Joaquim Bellmunt et al. · Annals of Oncology · 2019 · 182 citations · Full text

Medicine, Oncology, Urology +17

Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.

J Grøndahl-Hansen, Harry A. Peters, W L van Putten et al. · PubMed · 1995 · 174 citations

Medicine, Molecular Biology, Oncology +14

Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: A pilot study

Morten Quist, Mikael Rørth, Seppo W. Langer et al. · Lung Cancer · 2011 · 147 citations

Medicine, Oncology, Rehabilitation Medicine +16